sur PHAXIAM THERAPEUTICS (isin : FR001400K4B1)
Results of the Combined General Meeting of June 28, 2024
PHAXIAM Therapeutics, a biopharmaceutical company specializing in treatments against resistant bacterial infections, announced the results of its Combined General Meeting held on June 28, 2024. All resolutions recommended by the Board of Directors were adopted.
The resolutions include the approval of the annual accounts for the 2023 financial year and the confirmation of Valérie Faillat as Director. Shareholders also had to approve the executive remuneration policy and statutory modifications.
PHAXIAM has received authorization to issue shares and grant subscription options. Detailed voting results are available on the Company's website.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de PHAXIAM THERAPEUTICS